The eleventh-hour passage of the FDA Amendments Act of 2007 was a white-knuckle ride for the pharmaceutical and advertising industry lobbies, but by and large, one with a happy ending for business interests that feared draconian prohibitions on medical promotion.
Laboratory journals posted a 7% hike, while five of eight specialty markets posted moderate gains. PERQ/HCI’s Eugene M. May reports on the biggest specialty advertisers for the first six months of 2007
Scott A. Kale, Robert L. Barkin and Peggy Moyer discuss how sales reps oftentimes take the wrong approach in detailing their brands to doctors. The pharmaceutical sales paradigm hasn’t changed but physicians’ approach to practicing medicine has
Force in the Field
November 1, 2007
4:00 am
Less than a year after declaring it would cut one-fifth of its sales force, Pfizer has come out on top in a study of the most valued reps.
There hasn’t been much good news coming out of Pfizer in the past couple of years. Efforts to replace anticipated losses from the looming patent expirations of Lipitor and other products have taken ghastly and much-publicized turns.